Anticoagulation in transradial percutaneous coronary intervention


  • Conflict of interest: Darryn Appleton: none; Richard Cooke: none; Sunil Rao: Research funding – Ikaria, Sanofi-Aventis, Consultant – Terumo Medical, The Medicines Company, Zoll, Daiichi Sankyo, Lilly, Guerbet; Ion Jovin: none.


Transradial percutaneous coronary intervention (PCI) is associated with significant reductions in access site complications and major bleeding as compared with the transfemoral approach. Bivalirudin is now the most commonly used anticoagulant for transradial PCI in the United States, while weight adjusted unfractionated heparin remains the most common choice outside the United States. A growing number of reports suggest that transradial intervention may offer improved outcomes across a variety of clinical situations, including those at the highest risk of bleeding complications, such as those with acute myocardial infarction. The following review provides an overview of the studies evaluating anticoagulation in transradial PCI and a rationale for the combination of the transradial approach to coronary interventions with an optimal anticoagulant strategy to reduce both access site and nonaccess site-related bleeding. © 2013 Wiley Periodicals, Inc.